Protein C Concentrate (Human)
- Atc Codes:B01AD12
Table of contents
- Brand Names
- Drug Combinations
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Ceprotin; Belgium: Ceprotin; Czech Republic: Ceprotin; Denmark: Ceprotin; Estonia: Ceprotin; Finland: Ceprotin; France: Protexel; Germany: Ceprotin; Greece: Ceprotin; Hungary: Ceprotin; Ireland: Ceprotin; Italy: Ceprotin; Latvia: Ceprotin; Lithuania: Ceprotin; Luxembourg: Ceprotin; Netherlands: Ceprotin; Poland: Ceprotin; Portugal: Ceprotin; Romania: Ceprotin; Slovakia: Ceprotin; Spain: Ceprotín; Sweden: Ceprotin.
Asia
Japan: Anact C.
Drug combinations
Protein C Concentrate (Human) and Aprotinin
Protein C Concentrate (Human) and Fibrinogen
Protein C Concentrate (Human) and Tranexamic Acid
Protein C Concentrate (Human), Factor II, Factor VII, Factor IX, and Factor X
Chemistry
Pharmacologic Category
Anticoagulants, Miscellaneous. Enzyme. (ATC-Code: B01AD12).
Mechanism of action
Converted to activated protein C (APC). APC is serine protease which inactivates factors Va and VIIIa, limiting thrombotic formation. In vitro data also suggest inhibition of plasminogen activator inhibitor-1 (PAF-1) resulting in profibrinolytic activity, inhibition of macrophage production of tumor necrosis factor, blocking of leukocyte adhesion, and limitation of thrombin-induced inflammatory responses.
Therapeutic use
Replacement therapy for severe congenital protein C deficiency for prevention and/or treatment of venous thromboembolism and purpura fulminans.
Pregnancy and lactiation implications
Reproductive studies not performed. Unknown if administration during pregnancy results in fetal harm. Caution during lactation.
Unlabeled use
Contraindications
Hypersensitivity to protein C or any component of the formulation.
Warnings and precautions
Trace amounts of heparin contained within formulation may lead to heparin-induced thrombocytopenia. Formulation may contain trace amounts of mouse protein and/or heparin (hypersensitivity/allergic reactions might occur). Use caution in hepatic or renal impairment (not studied). Increased risk of bleeding may be seen in patients receiving concomitant anticoagulant therapy including thrombolytic agents, heparin, oral anticoagulants, glycoprotein IIb/IIIa antagonists, platelet aggregation inhibitors, and aspirin. Use with caution in sodium-restricted patients. Product of human plasma (may potentially contain infectious agents which could transmit disease).